Soft Tissue Sarcoma

This case highlights diagnostic pitfalls in cytokeratin-positive pleomorphic chest-wall tumors and the limitations of core biopsy. En bloc resection with rigid reconstruction is feasible, while positive margin status warrants multidisciplinary consideration of adjuvant local therapy and structured surveillance.

Definitive diagnosis was achieved following wide surgical excision, with histopathological and immunohistochemical analysis confirming MM (strongly positive for S100, Melan-A, and SOX10). This case highlights that MM must be considered in the differential diagnosis of atypical cystic soft tissue lesions, even in anatomically unexpected locations, especially in patients with predisposing conditions such as NF-1 and affirms the indispensable integration of multimodality imaging with histopathological and immunohistochemical correlation in resolving diagnostically challenging soft tissue masses.

DM skin is characterized by the deposition of immunoglobulins and complement C3c at sites of interface dermatitis, findings that are consistent with immune complex-mediated injury. MDA5 is widely expressed in both DM and control skin epidermis and can be detected in the infiltrating inflammatory cells of DM.

B7-H3 is a promising treatment target in sarcomas as it is highly expressed particular in high grade bone and soft tissue sarcomas, such as pleomorphic liposarcomas and osteosarcomas.

P1/2, N=55, National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis

P1, N=66, Not yet recruiting, Novartis Pharmaceuticals

Prognosis remains poor, with 5-year survival rates below 15% because of high recurrence and early metastatic potential. This case underscores the importance of maintaining a high index of suspicion for EA in nonhealing scalp lesions and highlights the central role of histopathology and immunohistochemistry in establishing the diagnosis.

Vignettes explored access to evidence-informed but not universally funded therapies: blinatumomab for low-risk relapse of B-cell acute lymphoblastic leukemia (B-ALL), larotrectinib for TRK-fused soft tissue sarcoma, PBT for unresectable head-and-neck sarcoma, and tisagenlecleucel for first relapse of B-ALL in a patient with Down syndrome. Access to evidence-informed cancer therapies for Canadian children remains variable. Universal funding, simplified approval processes, and the establishment of Canadian PBT centres to reduce travel burden, would ensure timely, equitable access to high-cost therapies.

Our group has been interested in utilizing the synthetic toll-like receptor 4 (TLR4) agonist, glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE), in patients with advanced STSs...Together, these findings demonstrate the potential of IT GLA-SE to elicit antigen-specific T cell clonal expansion as a component of immunotherapeutic strategies to combat metastatic STSs. Expanded studies are needed to explore the clinical and immunologic effects of IT GLA-SE, particularly in combination with other immunotherapies.

P1, N=25, Recruiting, University of California, Irvine

P2, N=42, Not yet recruiting, Centre Paul Strauss | Trial completion date: Jun 2032 --> Jun 2033 | Trial primary completion date: Oct 2027 --> Oct 2028

Clinical translation of these findings as well as conduction of further preclinical research requires an international, multidisciplinary collaborative effort to propel preclinical and clinical studies. This review was conducted by the DSRCT Working Group of OCTOPUS ("Optimising Combination Therapy fOr Paediatric, adolescent and yoUng adult patients with non-rhabdomyosarcoma soft tissue Sarcomas") to consolidate existing knowledge on preclinical translational aspects of DSRCT and guide future cooperative research.